Global investors including Novo Holdings and GIC are in talks to acquire a 10-12% stake in Hyderabad-based AIG Hospitals. The deal values the healthcare provider at up to ₹24,000 crore, reflecting strong international interest in India's medical infrastructure. The valuation is based on aggressive future growth targets, which investors will monitor closely alongside the company's capital spending plans.
Global investment firms, including Denmark’s Novo Holdings and Singapore’s sovereign wealth fund GIC, are in advanced discussions to acquire a minority stake in AIG Hospitals. The deal, which could see an infusion of ₹2,000 crore to ₹2,500 crore, involves a secondary sale by the company's founders, Duvvur Nageshwar Reddy and Penmetsa Venkata Subbaraju. The transaction would value the Hyderabad-based multi-specialty healthcare chain between ₹22,000 crore and ₹24,000 crore.
The structure of this potential deal is part of a broader portfolio reorganisation led by the Swedish buyout firm EQT. EQT, which acquired Baring Private Equity Asia in 2022, is working with financial advisors Goldman Sachs and UBS to manage the transfer of this holding between funds. This type of move allows long-term investors to continue holding assets while providing liquidity to earlier fund investors.
The high valuation attached to this deal is notably tied to the company's ambitious financial goals, specifically a projected EBITDA of ₹1,000 crore by the financial year 2028. For investors, this structure highlights the premium placed on Indian healthcare assets, which are increasingly sought after due to the country's significant shortage of medical infrastructure. While this demand supports growth, it also introduces valuation risk if the company fails to meet its aggressive future profit targets.
AIG Hospitals, which has been in operation since 1994, currently manages over 1,400 beds in Hyderabad. To maintain its growth trajectory, the company has planned a capital spending program of ₹2,000 crore over the next five years to add 1,000 beds. This includes the development of a new facility in Visakhapatnam. While such expansion is necessary to capture market share, it also requires significant upfront cash, which can put pressure on financial flexibility and profit margins if the new facilities do not reach high utilization levels quickly.
Looking ahead, the success of this deal and the company's long-term value will depend on its ability to execute this large expansion project without cost overruns. Regulatory changes regarding healthcare pricing and the ability to retain skilled medical talent remain persistent challenges in the private hospital sector. Investors will likely track the company's progress on its bed-addition timeline and its ability to improve operational margins to meet the ambitious earnings projections that underpin this latest valuation.